Clinical, Dermoscopic, and Molecular Features of Acantholytic Squamous Cell Carcinoma: A Systematic Review.

acantholytic squamous cell carcinoma (aSCC) adenoid SCC pseudoangiosarcomatous SCC pseudoglandular SCC pseudovascular SCC skin cancer squamous cell carcinoma (SCC)

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Aug 2024
Historique:
received: 25 07 2024
revised: 16 08 2024
accepted: 20 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Acantholytic squamous cell carcinoma (aSCC) is a rare clinicopathological subtype of cutaneous squamous cell carcinoma, accounting for approximately 4.9% of all SCC cases. However, there are currently no standardized criteria for the diagnosis of aSCC. This systematic review is the first to summarize the clinical and molecular features of aSCC. A systematic search of Medline, Embase, Scopus, and PubMed was performed. All articles in English or French were included, with no restriction of publication date. All articles with original data pertaining to clinical or molecular characteristics of aSCC were included. Two reviewers screened articles and resolved conflicts. Our systematic review included 52 studies on the clinical and molecular features of aSCC, including a total of 482 patients (76% male, mean age at diagnosis 68.9 years): 430 cases assessed clinical features, while 149 cases assessed molecular features. The most common location of aSCC was the head and neck ( This systematic review summarizes the clinical characteristics and molecular features of aSCC. As clinical differentiation can be difficult, clinicopathological correlation with molecular markers may help ensure proper diagnosis.

Identifiants

pubmed: 39199675
pii: cancers16162905
doi: 10.3390/cancers16162905
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Terry Fox Research Institute
ID : 3253
Organisme : Fonds de Recherche du Québec - Santé
ID : 312768
Organisme : Fonds de Recherche du Québec - Santé
ID : 324151
Organisme : Cancer Research Society
ID : 1057090
Organisme : Montreal Dermatology Research Institute
ID : N/A
Organisme : Canadian Dermatology Foundation
ID : N/A
Organisme : CIHR
ID : N/A
Pays : Canada
Organisme : Jewish General Hospital
ID : N/A
Organisme : Jewish General Hospital Foundation
ID : N/A
Organisme : Lady Davis Institute
ID : N/A

Auteurs

Catherine Keying Zhu (CK)

Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.

Lorena Alexandra Mija (LA)

Faculty of Medicine, Université de Montréal, Montreal, QC H3T 1J4, Canada.

Santina Conte (S)

Faculty of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.

Sarah Ghezelbash (S)

Cancer Axis, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.
Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.

Bonika Nallanathan (B)

Cancer Axis, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.
Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.

Geneviève Fortier-Riberdy (G)

Division of Dermatology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, QC H3T 1J4, Canada.

Margaret Redpath (M)

Department of Pathology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.

Philippe Lefrançois (P)

Cancer Axis, Lady Davis Institute for Medical Research, Montreal, QC H3T 1E2, Canada.
Division of Dermatology, Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.
Department of Pharmacology & Therapeutics, McGill University, Montreal, QC H3T 1E2, Canada.
Division of Surgical & Interventional Sciences, Department of Medicine, McGill University, Montreal, QC H3T 1E2, Canada.

Classifications MeSH